The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Myeloma UK: exciting clinical trials investigating treatments for MM
Rakesh Popat, MD, PhD, from University College London, London, UK, provides us an insight into the Clinical Trial Network run by Myeloma UK with the aim of effectively treating diseases including multiple myeloma (MM). Trials mentioned by Dr. Popat include the MUK9b trial (NCT03188172), evaluating the combination of daratumumab, revlimid and dexamethasone in treating MM, and the MUK8 trial (NCT02461888), which is investigating ixazomib in combination with cyclophosphamide and dexamethasone for the treatment of MM. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
